Is it appropriate to restart spironolactone after it has been discontinued for several weeks?

Restarting Spironolactone After Discontinuation

Yes, spironolactone can and should be restarted after a few weeks of discontinuation if the original indication persists, provided you first verify that renal function and serum potassium are within acceptable parameters.

Pre-Restart Assessment

Before reinitiating spironolactone, you must check:

• Serum potassium: Must be ≤5.0 mEq/L 1, 2, 1
• Renal function: Creatinine should be <2.5 mg/dL (or <220 μmol/L) 1, 2, 1
• Estimated GFR: Should be >30 mL/min/1.73 m² 3

These parameters are critical because the primary reasons for spironolactone discontinuation are hyperkalemia and worsening renal function, which occur more frequently in clinical practice than in randomized trials 1.

Restart Protocol

Follow the same initiation protocol as for new starts 1, 2, 1:

1. Starting dose: 25 mg once daily
2. Initial monitoring: Check renal function and electrolytes at 1 week and 4 weeks after restart
3. Dose titration: Consider increasing to 50 mg daily after 4-8 weeks if:
   • Potassium remains ≤5.5 mEq/L
   • Creatinine remains <220 μmol/L (2.5 mg/dL)
   • Patient tolerates current dose
4. Ongoing monitoring: Check labs at 1,2,3, and 6 months after achieving maintenance dose, then every 6 months 1, 2, 1

Clinical Context Matters

The decision to restart depends on why it was stopped:

If Stopped Due to Adverse Effects:

• Hyperkalemia (K >6.0 mEq/L): Wait until potassium normalizes to <5.0 mEq/L, then restart at 25 mg daily or 25 mg every other day 1, 2, 1
• Worsening renal function (Cr >310 μmol/L): Wait until creatinine improves to <220 μmol/L before considering restart 1, 2, 1
• Gynecomastia: Consider switching to eplerenone instead of restarting spironolactone 1, 2, 1
• Hypotension: Ensure blood pressure is stable; may need to space out medications or adjust other antihypertensives 3

If Stopped for Non-Medical Reasons:

If spironolactone was discontinued for reasons unrelated to adverse effects (e.g., patient non-adherence, medication access issues), restart is straightforward once the original indication is confirmed.

Importance of Continuation

The evidence strongly supports restarting spironolactone when indicated. In heart failure with reduced ejection fraction (HFrEF), spironolactone reduces:

• All-cause mortality by 30% 1
• Heart failure hospitalizations by 35% 1
• Number needed to treat: 9 patients for 2 years to prevent 1 death 1

Importantly, discontinuation of spironolactone is associated with a 2-4 fold higher risk of subsequent adverse cardiovascular events 3. This underscores the critical importance of maintaining therapy when clinically appropriate.

Common Pitfalls to Avoid

1. Failing to monitor electrolytes closely: The risk of hyperkalemia is highest in the first few weeks after initiation or dose changes 1, 4
2. Restarting at too high a dose: Always restart at 25 mg daily, even if the patient was previously on 50 mg 1, 2, 1
3. Inadequate patient education: Patients should avoid potassium supplements, salt substitutes containing potassium, and NSAIDs 4
4. Ignoring concomitant medications: ACE inhibitors, ARBs, and ARNIs increase hyperkalemia risk; closer monitoring is needed 1, 4

Special Populations

• Elderly patients: Higher risk of hyperkalemia and renal dysfunction; consider more frequent monitoring 1
• Low blood pressure: If symptomatic hypotension is present, address this first by spacing medications or adjusting other agents before restarting 3
• HFmrEF/HFpEF: Restart is reasonable, particularly in patients with LVEF on the lower end of the spectrum (41-49%) 5

The key principle is that spironolactone should be continued or restarted whenever the clinical indication persists and laboratory parameters permit, as the mortality and morbidity benefits are substantial and well-established 4.